The Non-Malignant Channel is supported with funding from Agios (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2022 | The safety and efficacy of etavopivat in SCD

Name: The safety and efficacy of etavopivat in SCD
Uploaded: 2022-06-21T00:00:00Z
Duration: 59 s
Description: Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, briefly discusses the safety and efficacy of etavopivat in sickle cell disease (SCD), highlighting the mechanism of action of this agent and promising activity observed in various studies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Santosh Saraf • 21 Jun 2022

EHA 2022

Non-Malignant Sickle Cell Disease Etavopivat

Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, briefly discusses the safety and efficacy of etavopivat in sickle cell disease (SCD), highlighting the mechanism of action of this agent and promising activity observed in various studies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding support from FORMA, Global Blood Therapeutics, Novartis, and Pfizer
Serves as a consultant or on an advisory board for Agios, FORMA, Global Blood Therapeutics, Novartis, and ORIC